InsiderTrades

Form 4 for LGND LIGAND PHARMACEUTICALS INC

Accepted 2026-08-14 17:05:08 ET · period of report 2026-08-12 · accession 0002001011-26-000115 · SEC index · Original document

Summary rows

Aggregated the way they appear in lists: one row per insider, transaction code and security table.

X Filed Traded Ticker Insider Title Type Price Qty Owned ΔOwn Value
DMT 2026-08-14 17:05 2026-08-12 LGND Espinoza Octavio CFO M - OptEx $56.91 +31.6K 59.3K +114% +$1.80M
DT 2026-08-14 17:05 2026-08-12 LGND Espinoza Octavio CFO S - Sale+OE $292.06 -31.6K 27.7K -53% -$9.24M
DMT 2026-08-14 17:05 2026-08-12 LGND Espinoza Octavio CFO M - OptEx $0.00 -31.6K 0 -100% $0

Purchase Sale Sale after option exercise All abbreviations

Every reported transaction

#TableSecurityDateCodeA/DSharesPriceOwned afterOwnExercise / expiryUnderlyingFootnotes
1 Common Common Stock 2026-08-12 M A 16,179 $52.84 43,875 D — — (F1) The transactions reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on May 13, 2026, in accordance with Rule 10b5-1.
2 Common Common Stock 2026-08-12 M A 2,074 $70.04 45,949 D — — (F1) The transactions reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on May 13, 2026, in accordance with Rule 10b5-1.
3 Common Common Stock 2026-08-12 M A 2,869 $55.75 48,818 D — — (F1) The transactions reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on May 13, 2026, in accordance with Rule 10b5-1.
4 Common Common Stock 2026-08-12 M A 7,171 $57.22 55,989 D — — (F1) The transactions reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on May 13, 2026, in accordance with Rule 10b5-1.
5 Common Common Stock 2026-08-12 M A 3,348 $68.74 59,337 D — — (F1) The transactions reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on May 13, 2026, in accordance with Rule 10b5-1.
6 Common Common Stock 2026-08-12 S D 31,641 $292.06 27,696 D — — (F1) The transactions reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on May 13, 2026, in accordance with Rule 10b5-1. (F2) The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $292.0098 to $292.0846. The Reporting Person undertakes to provide the Registrant, any securityholder of the Registrant, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
7 Derivative Employee Stock Option (right to buy) 2026-08-12 M D 2,869 $0.00 0 D $55.75 · — to 2030-02-13 2,869 Common Stock (F1) The transactions reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on May 13, 2026, in accordance with Rule 10b5-1. (F3) The original grant of 4,039 stock options vests and is exercisable as to approximately 15% of the underlying shares on August 13, 2020, approximately 70% of the underlying shares in 28 substantially equal monthly installments beginning on September 13, 2020, and approximately 15% of the underlying shares in 12 substantially equal monthly installments thereafter.
8 Derivative Employee Stock Option (right to buy) 2026-08-12 M D 7,171 $0.00 0 D $57.22 · — to 2030-10-01 7,171 Common Stock (F1) The transactions reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on May 13, 2026, in accordance with Rule 10b5-1. (F4) The stock option vests and is exercisable as to approximately 14% of the underlying shares on April 1, 2021, approximately 73% of the underlying shares in 32 substantially equal monthly installments on May 5, 2021, and approximately 13% of the underlying shares in 10 substantially equal monthly installments thereafter.
9 Derivative Non-Qualified Stock Option (right to buy) 2026-08-12 M D 16,179 $0.00 0 D $52.84 · — to 2032-05-05 16,179 Common Stock (F1) The transactions reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on May 13, 2026, in accordance with Rule 10b5-1. (F5) The stock option vests and is exercisable as to approximately 14% of the underlying shares on August 5, 2022, approximately 64% of the underlying shares in 28 substantially equal monthly installments beginning on September 5, 2022, and approximately 22% of the underlying shares in 12 substantially equal monthly installments thereafter.
10 Derivative Non-Qualified Stock Option (right to buy) 2026-08-12 M D 3,348 $0.00 0 D $68.74 · — to 2029-02-11 3,348 Common Stock (F1) The transactions reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on May 13, 2026, in accordance with Rule 10b5-1. (F6) The stock option vests and is exercisable as to approximately 13% of the underlying shares on August 11, 2019, and the remaining of the underlying shares in 40 substantially equal monthly installments thereafter.
11 Derivative Non-Qualified Stock Option (right to buy) 2026-08-12 M D 2,074 $0.00 0 D $70.04 · — to 2029-02-01 2,074 Common Stock (F1) The transactions reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on May 13, 2026, in accordance with Rule 10b5-1. (F7) The stock option vests and is exercisable as to approximately 16% of the underlying shares on August 1, 2019, approximately 74% of the underlying shares in 28 substantially equal monthly installments beginning on September 1, 2019, and approximately 10% of the underlying shares in 12 substantially equal monthly installments thereafter.